EGFR and non-small cell lung carcinoma: Furmomertinib, a novel third-generation EGFR TKI, is currently under evaluation in the phase III study FORWARD in EGFR mutant patients with stage from IIA to IIIA NSCLC after complete resection (NCT04853342).